Cargando…

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report

Most childhood cancer survivors who undergo hematopoietic stem cell transplantation subsequently develop impaired glucose tolerance and hypertriglyceridemia. These conditions are presumably associated with total-body irradiation–related acquired lipodystrophy and may lead to cardiovascular disease....

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagayama, Ayako, Ashida, Kenji, Moritaka, Kanoko, Hidaka, Mami, Gobaru, Mizuki, Tanaka, Seiji, Hasuzawa, Nao, Akasu, Shoko, Goto, Yuka, Motomura, Seiichi, Hara, Kento, Tsuruta, Munehisa, Wada, Nobuhiko, Nakayama, Hitomi, Tajiri, Yuji, Nomura, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830041/ https://www.ncbi.nlm.nih.gov/pubmed/31720553 http://dx.doi.org/10.1210/js.2019-00251

Ejemplares similares

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Human Leukocyte Antigen (HLA) Subtype-Dependent Development of Myasthenia Gravis, Type-1 Diabetes Mellitus, and Hashimoto Disease: A Case Report of Autoimmune Polyendocrine Syndrome Type 3
por: Gobaru, Mizuki, et al.
Publicado: (2019)

Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
por: Goto, Yuka, et al.
Publicado: (2020)

Metyrosine-associated endocrinological changes in pheochromocytoma and paraganglioma
por: Matsuo, Yuko, et al.
Publicado: (2023)

Metreleptin therapy in LMNA-linked lipodystrophies
por: Vatier, Camille, et al.
Publicado: (2015)

Eruptive xanthomas as a marker for metabolic disorders: A specific form of xanthoma that reflects hypertriglyceridemia
por: Ohtaki, Sohichiroh, et al.
Publicado: (2022)

Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017)

Pasireotide‐induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist for treatment
por: Shikata, Masato, et al.
Publicado: (2020)

New advances in the treatment of generalized lipodystrophy: role of metreleptin
por: Rodriguez, Alexander J, et al.
Publicado: (2015)

Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy
por: Vieira, Diana Branco, et al.
Publicado: (2022)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
por: Schweisberger, Cintya, et al.
Publicado: (2021)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy
por: Schlögl, Haiko, et al.
Publicado: (2023)

SAT089 Natural History Of Generalized Lipodystrophy Following Early Vs. Late Metreleptin Treatment
por: Brush, Maiah, et al.
Publicado: (2023)

Necessity of Utilizing Physiological Glucocorticoids for Managing Familial Mediterranean Fever
por: Ashida, Kenji, et al.
Publicado: (2020)

Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring
por: Yamada, Kentaro, et al.
Publicado: (2015)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report
por: Pedicelli, Stefania, et al.
Publicado: (2020)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Thyroid-related ophthalmopathy development in concurrence with growth hormone administration
por: Iwata, Shimpei, et al.
Publicado: (2021)

Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real‐life experience from a national reference network
por: Mosbah, Héléna, et al.
Publicado: (2022)

Clodronate, an inhibitor of the vesicular nucleotide transporter, ameliorates steatohepatitis and acute liver injury
por: Hasuzawa, Nao, et al.
Publicado: (2021)

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance
por: Lambadiari, Vaia, et al.
Publicado: (2021)

Case Report: Myxedema Coma Caused by Immunoglobulin A Vasculitis in a Patient With Severe Hypothyroidism
por: Ito, Hiroshi, et al.
Publicado: (2022)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

IgG4-Related Membranous Nephropathy with Acute Nephrotic Syndrome During Successful Steroid Maintenance Treatment for Type 1 Autoimmune Pancreatitis
por: Ito, Hiroshi, et al.
Publicado: (2023)

Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes
por: Vatier, Camille, et al.
Publicado: (2019)

The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges
por: Haymond, Morey W, et al.
Publicado: (2023)

Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the BSCL2 Gene: Results From the First-year
por: Özalkak, Şervan, et al.
Publicado: (2023)

Brown adipose activation and reversible beige coloration in adipose tissue with multiple accumulations of (18)F‐fluorodeoxyglucose in sporadic paraganglioma: A case report
por: Terada, Eriko, et al.
Publicado: (2019)

Transient Antidiuretic Hormone Insufficiency Caused by Severe Hyperosmolar Hyperglycemic Syndrome Based on Nephrogenic Diabetes Insipidus
por: Gobaru, Mizuki, et al.
Publicado: (2021)

Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports
por: Shibata, Yusuke, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q216fao3105cmo2ougkk6v22pd